{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:25:04Z","timestamp":1793762704599,"version":"4.6.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]},{"name":"SATT AXLR","award":["0682"],"award-info":[{"award-number":["0682"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-024-01648-9","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:07:48Z","timestamp":1736154468000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Allison","family":"Carles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Freyssin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra","family":"Guehairia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vignes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Hirbec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Rubinstenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangui","family":"Maurice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"1648_CR1","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","volume":"88","author":"R Brookmeyer","year":"1998","unstructured":"Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer\u2019s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337\u201342.","journal-title":"Am J Public Health"},{"key":"1648_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25:59\u201370.","journal-title":"Eur J Neurol"},{"key":"1648_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","volume":"6","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ. The molecular pathology of Alzheimer\u2019s disease. Neuron. 1991;6:487\u201398.","journal-title":"Neuron"},{"key":"1648_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ncb1104-1054","volume":"6","author":"DJ Selkoe","year":"2004","unstructured":"Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer\u2019s and Parkinson\u2019s diseases. Nat Cell Biol. 2004;6:1054\u201361.","journal-title":"Nat Cell Biol"},{"key":"1648_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yu Y. Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J Neuroinflammation. 2023;20:165.","journal-title":"J Neuroinflammation"},{"issue":"23","key":"1648_CR6","first-page":"00870","volume":"S0035\u20133787","author":"D Gouilly","year":"2023","unstructured":"Gouilly D, Rafiq M, Nogueira L, Salabert AS, Payoux P, P\u00e9ran P, Pariente J. Beyond the amyloid cascade: an update of Alzheimer\u2019s disease pathophysiology. Rev Neurol (Paris). 2023;S0035\u20133787(23):00870\u20136.","journal-title":"Rev Neurol (Paris)"},{"key":"1648_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/biomedicines11051398","volume":"11","author":"Y Ratan","year":"2023","unstructured":"Ratan Y, Rajput A, Maleysm S, Pareek A, Jain V, Pareek A, Kaur R, Singh G. An insight into cellular and molecular mechanisms underlying the pathogenesis of neurodegeneration in Alzheimer\u2019s disease. Biomedicines. 2023;11:1398.","journal-title":"Biomedicines"},{"key":"1648_CR8","doi-asserted-by":"publisher","first-page":"12845","DOI":"10.1074\/jbc.M808759200","volume":"284","author":"B Frost","year":"2009","unstructured":"Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845\u201352.","journal-title":"J Biol Chem"},{"key":"1648_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20:148\u201360.","journal-title":"Nat Rev Neurosci"},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505\u20138.","journal-title":"JAMA Neurol"},{"key":"1648_CR11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fnins.2017.00626","volume":"11","author":"J Avila","year":"2017","unstructured":"Avila J, Llorens-Mart\u00edn M, Pallas-Bazarra N, Bol\u00f3s M, Perea JR, Rodr\u00edguez-Matell\u00e1n A, Hern\u00e1ndez F. Cognitive decline in neuronal aging and Alzheimer\u2019s disease: role of NMDA receptors and associated proteins. Front Neurosci. 2017;11:626.","journal-title":"Front Neurosci"},{"key":"1648_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2017","unstructured":"Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57:1041\u20138.","journal-title":"J Alzheimers Dis"},{"key":"1648_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0197-4580(89)90144-9","volume":"10","author":"CW Cotman","year":"1989","unstructured":"Cotman CW, Geddes JW, Bridges RJ, Monaghan DT. N-methyl-D-aspartate receptors and Alzheimer\u2019s disease. Neurobiol Aging. 1989;10:603\u20135.","journal-title":"Neurobiol Aging"},{"issue":"6407","key":"1648_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/361031a0","volume":"361","author":"TV Bliss","year":"1993","unstructured":"Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31\u20139.","journal-title":"Nature"},{"key":"1648_CR15","doi-asserted-by":"publisher","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","volume":"110","author":"M Talantova","year":"2013","unstructured":"Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Pi\u00f1a-Crespo JC, Lipton SA. A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA. 2013;110:E2518\u201327.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1648_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1385\/MN:24:1-3:107","volume":"24","author":"R Sattler","year":"2001","unstructured":"Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol. 2001;24:107\u201329.","journal-title":"Mol Neurobiol"},{"key":"1648_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0074-7742(07)82003-4","volume":"82","author":"S Vesce","year":"2007","unstructured":"Vesce S, Rossi D, Brambilla L, Volterra A. Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol. 2007;82:57\u201371.","journal-title":"Int Rev Neurobiol"},{"key":"1648_CR18","doi-asserted-by":"crossref","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZERALZ 2 randomized clinical trial. J Am Med Assoc. 2023;330:512\u201327.","DOI":"10.1001\/jama.2023.13239"},{"key":"1648_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med."},{"key":"1648_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13:98.","journal-title":"Alzheimers Res Ther."},{"key":"1648_CR21","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/gps.938","volume":"18","author":"W Danysz","year":"2003","unstructured":"Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer\u2019s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18:S23-32.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1648_CR22","doi-asserted-by":"publisher","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","volume":"30","author":"P Xia","year":"2010","unstructured":"Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246\u201350.","journal-title":"J Neurosci"},{"key":"1648_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","volume":"82","author":"MP Parsons","year":"2014","unstructured":"Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron. 2014;82:279\u201393.","journal-title":"Neuron"},{"key":"1648_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0969-8051(01)00293-1","volume":"29","author":"SM Ametamey","year":"2002","unstructured":"Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M, Buck A, Burger C, Samnick S, Quack G, Schubiger PA. PET studies of 18F-Memantine in healthy volunteers. Nucl Med Biol. 2002;29:227\u201331.","journal-title":"Nucl Med Biol"},{"key":"1648_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0969-8051(98)00003-1","volume":"25","author":"S Samnick","year":"1998","unstructured":"Samnick S, Ametamey S, Leenders KL, Vontobel P, Quack G, Parsons CG, Neu H, Schubiger PA. Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): a potential radioligand for mapping the NMDA-receptor complex. Nucl Med Biol. 1998;25:323\u201330.","journal-title":"Nucl Med Biol"},{"key":"1648_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nucmedbio.2015.04.001","volume":"42","author":"AS Salabert","year":"2015","unstructured":"Salabert AS, Fonta C, Fontan C, Adel D, Alonso M, Pestourie C, Belhadj-Tahar H, Tafani M, Payoux P. Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors. Nucl Med Biol. 2015;42:643\u201353.","journal-title":"Nucl Med Biol"},{"key":"1648_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.12.003","volume":"59","author":"AS Salabert","year":"2018","unstructured":"Salabert AS, Mora-Ramirez E, Beaurain M, Alonso M, Fontan C, Tahar HB, Boizeau ML, Tafani M, Bardi\u00e8s M, Payoux P. Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats. Nucl Med Biol. 2018;59:1\u20138.","journal-title":"Nucl Med Biol"},{"key":"1648_CR28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11307-023-01811-y","volume":"25","author":"M Beaurain","year":"2023","unstructured":"Beaurain M, Talmont F, Pierre D, P\u00e9ran P, Boucher S, Hitzel A, Rols MP, Cuvillier O, Payoux P, Salabert AS. Pharmacological characterization of [18F]-FNM and evaluation of NMDA receptors activation in a rat brain injury model. Mol Imaging Biol. 2023;25:692\u2013703.","journal-title":"Mol Imaging Biol"},{"key":"1648_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/ijnp\/pyab007","volume":"24","author":"BK Chen","year":"2021","unstructured":"Chen BK, Le Pen G, Eckmier A, Rubinstenn G, Jay TM, Denny CA. Fluoroethylnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits. Int J Neuropsychopharmacol. 2021;24:519\u201331.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1648_CR30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.biopsych.2021.04.024","volume":"90","author":"BK Chen","year":"2021","unstructured":"Chen BK, Luna VM, Shannon ME, Hunsberger HC, Mastrodonato A, Stackmann M, McGowan JC, Rubinstenn G, Denny CA. Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior. Biol Psychiatr. 2021;90:458\u201372.","journal-title":"Biol Psychiatr"},{"key":"1648_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/ijnp\/pyaa075","volume":"24","author":"S Couly","year":"2021","unstructured":"Couly S, Denus M, Bouchet M, Rubinstenn G, Maurice T. Anti-amnesic and neuroprotective effects of Fluoroethylnormemantine in a pharmacological mouse model of Alzheimer\u2019s disease. Int J Neuropsychopharmacol. 2021;24:142\u201357.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1648_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0006-8993(95)01032-7","volume":"706","author":"T Maurice","year":"1996","unstructured":"Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally administered \u03b2-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996;706:181\u201393.","journal-title":"Brain Res"},{"key":"1648_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","volume":"149","author":"J Meunier","year":"2006","unstructured":"Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid \u03b225-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol. 2006;149:998\u20131012.","journal-title":"Br J Pharmacol"},{"key":"1648_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0269881110379286","volume":"25","author":"V Villard","year":"2011","unstructured":"Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011;25:1101\u201317.","journal-title":"J Psychopharmacol"},{"key":"1648_CR35","first-page":"231","volume":"55","author":"Y Rodr\u00edguez Cruz","year":"2017","unstructured":"Rodr\u00edguez Cruz Y, Strehaiano M, Rodr\u00edguez Obaya T, Garc\u00eda Rodr\u00edguez JC, Maurice T. An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer\u2019s disease. J Alz Dis. 2017;55:231\u201348.","journal-title":"J Alz Dis"},{"key":"1648_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.phrs.2019.04.026","volume":"144","author":"T Maurice","year":"2019","unstructured":"Maurice T, Volle JN, Strehaiano M, Crouzier L, Pereira C, Kaloyanov N, Virieux D, Pirat JL. Neuroprotection innon-transgenic and transgenic mouse models of Alzheimer\u2019s disease by positivemodulation of \u03c31 receptors. Pharmacol Res. 2019;144:315\u201330.","journal-title":"Pharmacol Res"},{"key":"1648_CR37","first-page":"773","volume":"41","author":"K Ditzler","year":"1991","unstructured":"Ditzler K. Efficacy and tolerability ofmemantine in patients with dementia syndrome. A double-blind, placebocontrolled trial. Arzneimittelforschung. 1991;41:773\u201380.","journal-title":"Arzneimittelforschung"},{"key":"1648_CR38","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1002\/cam4.5619","volume":"12","author":"ZM Nakamura","year":"2023","unstructured":"Nakamura ZM, Deal AM, Park EM, Stanton KE, Lopez YE, Quillen LJ, O\u2019Hare Kelly E, Heiling HM, Nyrop KA, Ray EM, Dees EC, Reeder-Hayes KE, Jolly TA, Carey LA, Abdou Y, Olajide OA, Rauch JK, Joseph R, Copeland A, McNamara MA, Ahles TA, Muss HB. A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects. Cancer Med. 2023;12:8172\u201383.","journal-title":"Cancer Med"},{"key":"1648_CR39","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jamda.2014.11.002","volume":"16","author":"C Ballard","year":"2015","unstructured":"Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, Creese B, Loughlin P, Bannister C, Burns A, Win SN, Walker Z, MAIN-AD investigators,. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer\u2019s disease (MAIN-AD). J Am Med Dir Assoc. 2015;16:316\u201322.","journal-title":"J Am Med Dir Assoc"},{"key":"1648_CR40","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1185\/030079907X233403","volume":"23","author":"G Small","year":"2007","unstructured":"Small G, Dubois B. A review of compliance to treatment in Alzheimer\u2019s disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007;23:2705\u201313.","journal-title":"Curr Med Res Opin"},{"key":"1648_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/gps.1788","volume":"22","author":"B Winblad","year":"2007","unstructured":"Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456\u201367.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1648_CR42","doi-asserted-by":"publisher","first-page":"RRN1291","DOI":"10.1371\/currents.RRN1291","volume":"3","author":"MG Beconi","year":"2011","unstructured":"Beconi MG, Howland D, Park L, Lyons K, Giuliano J, Dominguez C, Munoz-Sanjuan I, Pacifici R. Pharmacokinetics of memantine in rats and mice. PLoS Curr. 2011;3:RRN1291.","journal-title":"PLoS Curr"},{"key":"1648_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/hmg\/ddh019","volume":"13","author":"JL Jankowsky","year":"2004","unstructured":"Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159\u201370.","journal-title":"Hum Mol Genet"},{"key":"1648_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbr.2004.06.020","volume":"157","author":"R Lalonde","year":"2005","unstructured":"Lalonde R, Dumont M, Staufenbiel M, Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005;157:91\u20138.","journal-title":"Behav Brain Res"},{"key":"1648_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.nbd.2006.08.017","volume":"24","author":"M Garcia-Alloza","year":"2006","unstructured":"Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP. Characterization of amyloid deposition in the APPswe\/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24:516\u201324.","journal-title":"Neurobiol Dis"},{"key":"1648_CR46","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.neurobiolaging.2008.08.005","volume":"31","author":"A Volianskis","year":"2010","unstructured":"Volianskis A, K\u00f8stner R, M\u00f8lgaard M, Hass S, Jensen MS. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe\/PS1\u03b4E9-deleted transgenic mice model of \u00df-amyloidosis. Neurobiol Aging. 2010;31:1173\u201387.","journal-title":"Neurobiol Aging"},{"key":"1648_CR47","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. NC3Rs reporting guidelines working group. animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577\u20139.","journal-title":"Br J Pharmacol"},{"key":"1648_CR48","unstructured":"Paxinos G, Franklin KB. Paxinos and Franklin's the mouse brain in stereotaxic coordinates. Academic press. 5th Edition - April 6, 2019. 2019. ISBN: 9780128161579."},{"key":"1648_CR49","doi-asserted-by":"crossref","unstructured":"Gilda JE, Gomes AV. Stain-Free total protein staining is a superior loading control to \u03b2-actin for Western blots. Anal Biochem. 2013;440:186\u20138.","DOI":"10.1016\/j.ab.2013.05.027"},{"key":"1648_CR50","doi-asserted-by":"crossref","unstructured":"G\u00fcrtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald K, Kohn JE, Posch A. Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem. 2013;433:105\u201311.","DOI":"10.1016\/j.ab.2012.10.010"},{"key":"1648_CR51","doi-asserted-by":"publisher","first-page":"e74667","DOI":"10.1371\/journal.pone.0074667","volume":"8","author":"N Crouzin","year":"2013","unstructured":"Crouzin N, Baranger K, Cavalier M, Marchalant Y, Cohen-Solal C, Roman FS, Khrestchatisky M, Rivera S, F\u00e9ron F, Vignes M. Area-specific alterations of synaptic plasticity in the 5XFAD mouse model of Alzheimer\u2019s disease: dissociation between somatosensory cortex and hippocampus. PLoS ONE. 2013;8:e74667.","journal-title":"PLoS ONE"},{"key":"1648_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1196\/annals.1427.002","volume":"1147","author":"DG Nicholls","year":"2008","unstructured":"Nicholls DG. Oxidative stress and energy crises in neuronal dysfunction. Ann N Y Acad Sci. 2008;1147:53\u201360.","journal-title":"Ann N Y Acad Sci"},{"key":"1648_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00401-011-0843-x","volume":"122","author":"CY Shao","year":"2011","unstructured":"Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurdsson EM. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced A\u03b2 and tau pathology in transgenic mouse models of Alzheimer\u2019s disease. Acta Neuropathol. 2011;122:285\u201392.","journal-title":"Acta Neuropathol"},{"key":"1648_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/JAD-2010-100948","volume":"22","author":"J Liu","year":"2010","unstructured":"Liu J, Chang L, Roselli F, Almeida OF, Gao X, Wang X, Yew DT, Wu Y. Amyloid-\u03b2 induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors. J Alzheimers Dis. 2010;22:541\u201356.","journal-title":"J Alzheimers Dis"},{"key":"1648_CR55","doi-asserted-by":"publisher","first-page":"137030","DOI":"10.1016\/j.neulet.2022.137030","volume":"795","author":"E Ram\u00edrez-Hern\u00e1ndez","year":"2023","unstructured":"Ram\u00edrez-Hern\u00e1ndez E, S\u00e1nchez-Maldonado C, Patricio-Mart\u00ednez A, Lim\u00f3n ID. Amyloid-\u03b225-35 induces the morphological alteration of dendritic spines and decreases NR2B and PSD-95 expression in the hippocampus. Neurosci Lett. 2023;795:137030.","journal-title":"Neurosci Lett"},{"key":"1648_CR56","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1126\/science.7569905","volume":"269","author":"HC Kornau","year":"1995","unstructured":"Kornau HC, Schenker LT, Kennedy MB, Seeburg PH. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995;269:1737\u201340.","journal-title":"Science"},{"key":"1648_CR57","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1523\/JNEUROSCI.16-07-02157.1996","volume":"16","author":"M Niethammer","year":"1996","unstructured":"Niethammer M, Kim E, Sheng M. Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD-95 family of membrane-associated guanylate kinases. J Neurosci. 1996;16:2157\u201363.","journal-title":"J Neurosci"},{"key":"1648_CR58","doi-asserted-by":"publisher","first-page":"109194","DOI":"10.1016\/j.celrep.2021.109194","volume":"35","author":"K Dore","year":"2021","unstructured":"Dore K, Carrico Z, Alfonso S, Marino M, Koymans K, Kessels HW, Malinow R. PSD-95 protects synapses from \u03b2-amyloid. Cell Rep. 2021;35:109194.","journal-title":"Cell Rep"},{"key":"1648_CR59","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nn1680","volume":"9","author":"I P\u00e9rez-Ota\u00f1o","year":"2006","unstructured":"P\u00e9rez-Ota\u00f1o I, Luj\u00e1n R, Tavalin SJ, Plomann M, Modregger J, Liu XB, Jones EG, Heinemann SF, Lo DC, Ehlers MD. Endocytosis and synaptic removal of NR3A-containing NMDA receptors by PAC-SIN1\/syndapin1. Nat Neurosci. 2006;9:611\u201321.","journal-title":"Nat Neurosci"},{"key":"1648_CR60","doi-asserted-by":"publisher","first-page":"e13005","DOI":"10.1111\/bpa.13005","volume":"31","author":"JHY Yeung","year":"2021","unstructured":"Yeung JHY, Walby JL, Palpagama TH, Turner C, Waldvogel HJ, Faull RLM, Kwakowsky A. Glutamatergic receptor expression changes in the Alzheimer\u2019s disease hippocampus and entorhinal cortex. Brain Pathol. 2021;31:e13005.","journal-title":"Brain Pathol"},{"key":"1648_CR61","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00441-006-0273-6","volume":"326","author":"G K\u00f6hr","year":"2006","unstructured":"K\u00f6hr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 2006;326:439\u201346.","journal-title":"Cell Tissue Res"},{"key":"1648_CR62","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.brainresbull.2012.10.005","volume":"93","author":"ES Vizi","year":"2013","unstructured":"Vizi ES, Kisfali M, L\u0151rincz T. Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects. Brain Res Bull. 2013;93:32\u20138.","journal-title":"Brain Res Bull"},{"key":"1648_CR63","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1096\/fj.08-107268","volume":"22","author":"F L\u00e9veill\u00e9","year":"2008","unstructured":"L\u00e9veill\u00e9 F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008;22:4258\u201371.","journal-title":"FASEB J"},{"key":"1648_CR64","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1152\/jn.00458.2019","volume":"123","author":"A McQuate","year":"2020","unstructured":"McQuate A, Barria A. Rapid exchange of synaptic and extrasynaptic NMDA receptors in hippocampal CA1 neurons. J Neurophysiol. 2020;123:1004\u201314.","journal-title":"J Neurophysiol"},{"key":"1648_CR65","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/nn1586","volume":"8","author":"HK Lee","year":"2005","unstructured":"Lee HK, Min SS, Gallagher M. Kirkwood A (2005) NMDA receptor-independent long-term depression correlates with successful aging in rats. Nat Neurosci. 2005;8:1657\u20139.","journal-title":"Nat Neurosci"},{"key":"1648_CR66","doi-asserted-by":"crossref","unstructured":"Papadia S, Stevenson P, Hardingham NR, Bading H, Hardingham GE. Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci. 25:4279\u201387.","DOI":"10.1523\/JNEUROSCI.5019-04.2005"},{"key":"1648_CR67","doi-asserted-by":"publisher","first-page":"20130601","DOI":"10.1098\/rstb.2013.0601","volume":"369","author":"T Papouin","year":"2014","unstructured":"Papouin T, Oliet SH. Organization, control and function of extrasynaptic NMDA receptors. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130601.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"1648_CR68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40478-018-0611-4","volume":"23","author":"MK M\u00fcller","year":"2018","unstructured":"M\u00fcller MK, Jacobi E, Sakimura K, Malinow R, von Engelhardt J. NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (A\u03b2) overexpressing mice. Acta Neuropathol Commun. 2018;23(6):110.","journal-title":"Acta Neuropathol Commun"},{"key":"1648_CR69","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s12035-015-9647-7","volume":"54","author":"Y Li","year":"2016","unstructured":"Li Y, Sun W, Han S, Li J, Ding S, Wang W, Yin,. IGF-1-involved negative feedback of NR2B NMDA subunits protects cultured hippocampal neurons against NMDA-induced excitotoxicity. Mol Neurobiol. 2016;54:684\u201396.","journal-title":"Mol Neurobiol"},{"key":"1648_CR70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuroscience.2018.03.011","volume":"380","author":"A Ravikrishnan","year":"2018","unstructured":"Ravikrishnan A, Gandhi PJ, Shelkar GP, Liu J, Pavuluri R, Dravid SM. Region-specific expression of NMDA receptor GluN2C Subunit in parvalbumin-positive neurons and astrocytes: analysis of GluN2C expression using a novel reporter model. Neuroscience. 2018;380:49\u201362.","journal-title":"Neuroscience"},{"key":"1648_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0031-6997(24)01394-2","volume":"51","author":"R Dingledine","year":"1999","unstructured":"Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7\u201361.","journal-title":"Pharmacol Rev"},{"key":"1648_CR72","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/ana.23626","volume":"72","author":"AM Kaindl","year":"2012","unstructured":"Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G, Le Charpentier T, Josserand J, Ali C, Vivien D, Collingridge GL, Lombet A, Issa L, Rene F, Loeffler JP, Kavelaars A, Verney C, Mantz J, Gressens P. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol. 2012;72:536\u201349.","journal-title":"Ann Neurol"},{"key":"1648_CR73","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1016\/j.molcel.2022.10.008","volume":"82","author":"TH Chou","year":"2022","unstructured":"Chou TH, Kang H, Simorowski N, Traynelis SF, Furukawa H. Structural insights into assembly and function of GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDARs. Mol Cell. 2022;82:4548-4563.e4.","journal-title":"Mol Cell"},{"key":"1648_CR74","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ceca.2009.12.010","volume":"47","author":"E Alberdi","year":"2010","unstructured":"Alberdi E, S\u00e1nchez-G\u00f3mez MV, Cavaliere F, P\u00e9rez-Samart\u00edn A, Zugaza JL, Trullas R, Domercq M, Matute C. Amyloid \u03b2 oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47:264\u201372.","journal-title":"Cell Calcium"},{"key":"1648_CR75","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1523\/JNEUROSCI.4814-07.2008","volume":"28","author":"T Bolmont","year":"2008","unstructured":"Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial\/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283\u201392.","journal-title":"J Neurosci"},{"key":"1648_CR76","doi-asserted-by":"publisher","first-page":"108833","DOI":"10.1016\/j.neuropharm.2021.108833","volume":"201","author":"AV Eapen","year":"2021","unstructured":"Eapen AV, Fern\u00e1ndez-Fern\u00e1ndez D, Georgiou J, Bortolotto ZA, Lightman S, Jane DE, Volianskis A, Collingridge GL. Multiple roles of GluN2D-containing NMDA receptors in short-term potentiation and long-term potentiation in mouse hippocampal slices. Neuropharmacology. 2021;201:108833.","journal-title":"Neuropharmacology"},{"key":"1648_CR77","doi-asserted-by":"publisher","first-page":"109737","DOI":"10.1016\/j.neuropharm.2023.109737","volume":"244","author":"P Karimi Tari","year":"2024","unstructured":"Karimi Tari P, Parsons CG, Collingridge GL, Rammes G. Memantine: Updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2024;244:109737.","journal-title":"Neuropharmacology"},{"key":"1648_CR78","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.neuropharm.2011.01.035","volume":"60","author":"M Filali","year":"2011","unstructured":"Filali M, Lalonde R, Rivest S. Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP\/PS1 mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2011;60:930\u20136.","journal-title":"Neuropharmacology"},{"key":"1648_CR79","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/jnr.21713","volume":"86","author":"H Scholtzova","year":"2008","unstructured":"Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, Quartermain D, Banerjee P, Wisniewski T. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer\u2019s-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res. 2008;86:2784\u201391.","journal-title":"J Neurosci Res"},{"key":"1648_CR80","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1523\/JNEUROSCI.0203-11.2011","volume":"31","author":"S Li","year":"2011","unstructured":"Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A\u03b2 oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627\u201338.","journal-title":"J Neurosci"},{"key":"1648_CR81","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1471-4159.2007.05147.x","volume":"105","author":"R Minkeviciene","year":"2008","unstructured":"Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, Iivonen H, Leguit N, Glennon J, Koistinaho J, Banerjee P, Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP\/PS1 transgenic and wild-type mice. J Neurochem. 2008;105:584\u201394.","journal-title":"J Neurochem"},{"key":"1648_CR82","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1006\/nbdi.2002.0481","volume":"9","author":"J Puoliv\u00e4li","year":"2002","unstructured":"Puoliv\u00e4li J, Wang J, Heikkinen T, Heikkil\u00e4 M, Tapiola T, van Groen T, Tanila H. Hippocampal Ab42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis. 2002;9:339\u201347.","journal-title":"Neurobiol Dis"},{"key":"1648_CR83","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova I, Karran E, De Strooper B. The toxic A\u03b2 oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349\u201357.","journal-title":"Nat Neurosci"},{"key":"1648_CR84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/alzrt272","volume":"6","author":"WF Goure","year":"2014","unstructured":"Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics. Alzheimers Res Ther. 2014;6:42.","journal-title":"Alzheimers Res Ther"},{"key":"1648_CR85","doi-asserted-by":"publisher","first-page":"23818","DOI":"10.1074\/jbc.M701078200","volume":"282","author":"IH Cheng","year":"2007","unstructured":"Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv\u00e4li J, Lesn\u00e9 S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-\u03b2 fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818\u201328.","journal-title":"J Biol Chem"},{"key":"1648_CR86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11064-018-2526-7","volume":"44","author":"HA Alsaad","year":"2019","unstructured":"Alsaad HA, DeKorver NW, Mao Z, Dravid SM, Arikkath J, Monaghan DT. In the Telencephalon, GluN2C NMDA Receptor Subunit mRNA is Predominately Expressed in Glial Cells and GluN2D mRNA in Interneurons. Neurochem Res. 2019;44:61\u201377.","journal-title":"Neurochem Res"},{"key":"1648_CR87","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/glia.24128","volume":"70","author":"MA Di Castro","year":"2022","unstructured":"Di Castro MA, Volterra A. Astrocyte control of the entorhinal cortex-dentate gyrus circuit: Relevance to cognitive processing and impairment in pathology. Glia. 2022;70:1536\u201353.","journal-title":"Glia"},{"key":"1648_CR88","doi-asserted-by":"publisher","first-page":"e3029","DOI":"10.1371\/journal.pone.0003029","volume":"3","author":"Y Yoshiike","year":"2008","unstructured":"Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, Takashima A. GABAA receptor-mediated acceleration of aging-associated memory decline in APP\/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One. 2008;3:e3029.","journal-title":"PLoS One"},{"key":"1648_CR89","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.neuron.2007.05.002","volume":"54","author":"S Ge","year":"2007","unstructured":"Ge S, Yang CH, Hsu KS, Ming GL, Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron. 2007;54:559\u201366.","journal-title":"Neuron"},{"key":"1648_CR90","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13195-023-01337-z","volume":"15","author":"Q Ji","year":"2023","unstructured":"Ji Q, Yang Y, Xiong Y, Zhang YJ, Jiang J, Zhou LP, Du XH, Wang CX, Zhu ZR. Blockade of adenosine A2A receptors reverses early spatial memory defects in the APP\/PS1 mouse model of Alzheimer\u2019s disease by promoting synaptic plasticity of adult-born granule cells. Alzheimers Res Ther. 2023;15:187.","journal-title":"Alzheimers Res Ther"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01648-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01648-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:27:40Z","timestamp":1736198860000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01648-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01648-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal procedures were conducted in adherence with the European Union Directive 2010\/63 and the ARRIVE guidelines and authorized by the National Ethic Committee (Paris, France): authorization APAFIS #30410\u20132021031516372048.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A.F. is employee of ReST Therapeutics. G.R. is co-inventor and owner of the patent FR2005138 (2022) and founder of ReST Therapeutics. T.M. is co-inventor of the patent FR2005138. Other authors declare that they have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}